CRC and IBD have been linked to the volatolome, which is a mixture of volatile organic compounds (VOCs). The volatolome seems to have promise as a non-invasive biomarker for the identification of CRC and IBD. Multiple researches have been conducted on the volatolome's potential, utilising either chemical analysis or pattern-recognition approaches to determine its potential. The existing literature on the potential of the volatolome as a cancer and inflammatory bowel disease (IBD) biomarker was examined. The survey examines 23 journal papers that were obtained electronically through major scientific databases such as PubMed, Google Scholar, Scopus, IEEE, and Science Direct, which were searched using sets of keywords. The papers were obtained through major scientific databases such as PubMed, Google Scholar, Scopus, IEEE, and Science Direct, which were searched using sets of keywords. Publication of the articles was made possible by the use of major scientific databases such as Pubmed and Google Scholar, as well as the IEEE and Science Direct. VOC analyses appear promising for future screening of CRC and IBD, with potentially improved test performances allowing for earlier detection of IBD and CRC and consequently earlier initiation of treatment, potentially reducing morbidity and mortality rates as well as lower rates of (unnecessary) colonoscopies, according to the studies included.